Int J Stomatol ›› 2022, Vol. 49 ›› Issue (5): 511-520.doi: 10.7518/gjkq.2022050

• Oral Microbiology • Previous Articles     Next Articles

Research progress on drug synergism with fluconazole in fluconazole-resistant Candida albicans

Yang Sirui1,2(),Ren Biao1,Peng Xian1,Xu Xin1,2()   

  1. 1.State Key Laboratory of Oral Diseass & National Clinical Resenrch Center for Oral Di-seases & West China School of Stomatology, Sichuan University, Chengdu 610041, China
    2.State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Dept. of Cariology and Endodontics, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
  • Received:2021-12-12 Revised:2022-04-15 Online:2022-09-01 Published:2022-09-16
  • Contact: Xin Xu;
  • Supported by:
    National Natural Science Foundation of China(81771099)


Candida albicans is the most common opportunistic pathogen in invasive infections. Azoles, especially fluconazole (FLC) is the most extensively used antifungal drug. However, with the increasingly reported drug resistance, combinatory use of other antifungals that synergize with FLC can reduce the dose and toxicity of both drugs. This strategy represents a promising approach to the management of drug-resistance emergence. This article reviews the common mechanisms of drug resistance developed by Candida albicans and discusses the progress of research on the discovery of drug synergism with FLC to provide reference for the development of novel antifungals.

Key words: Candida albicans, azole-resistant, efflux pump, biofilm

CLC Number: 

  • R 782.2


Fig 1

The common pathway of drug synergism with fluconazole"

1 Chen CY, Sheng WH, Tien FM, et al. Clinical characteristics and treatment outcomes of pulmonary invasive fungal infection among adult patients with hematological malignancy in a medical centre in Taiwan, 2008-2013[J]. J Microbiol Immunol Infect, 2020, 53(1): 106-114.
2 Blot M, Lanternier F, Lortholary O. Epidemiology of visceral fungal infection in France and in the world[J]. Rev Prat, 2015, 65(10): 1318-1321.
3 Yang CH, He XS, Chen J, et al. Fungal infection in patients after liver transplantation in years 2003 to 2012[J]. Ann Transplant, 2012, 17(4): 59-63.
4 Kamikawa Y, Mori Y, Nagayama T, et al. Frequency of clinically isolated strains of oral Candida species at Kagoshima University Hospital, Japan, and their susceptibility to antifungal drugs in 2006-2007 and 2012-2013[J]. BMC Oral Health, 2014, 14: 14.
5 Bernal-Trevino A, Gonzalez-Amaro AM, Mendez Gonzalez V, et al. Frequency of Candida in root canals of teeth with primary and persistent endodontic infections[J]. Rev Iberoam Micol, 2018, 35(2): 78-82.
6 Akins RA. An update on antifungal targets and mechanisms of resistance in Candida albicans [J]. Med Mycol, 2005, 43(4): 285-318.
7 Seebacher C. Action mechanisms of modern antifungal agents and resulting problems in the management of onychomycosis[J]. Mycoses, 2003, 46(11/12): 506-510.
8 Arendrup MC, Dzajic E, Jensen RH, et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme[J]. Clin Microbiol Infect, 2013, 19(8): E343-E353.
9 Sarkar S, Uppuluri P, Pierce CG, et al. In vitro study of sequential fluconazole and caspofungin treatment against Candida albicans biofilms[J]. Antimicrob Agents Chemother, 2014, 58(2): 1183-1186.
10 Longhi C, Santos JP, Morey AT, et al. Combination of fluconazole with silver nanoparticles produced by Fusarium oxysporum improves antifungal effect against planktonic cells and biofilm of drug-resistant Candida albicans [J]. Med Mycol, 2016, 54(4): 428-432.
11 Wei GX, Xu X, Wu CD. In vitro synergism between berberine and miconazole against planktonic and biofilm Candida cultures[J]. Arch Oral Biol, 2011, 56(6): 565-572.
12 Cowen LE, Sanglard D, Howard SJ, et al. Mechanisms of antifungal drug resistance[J]. Cold Spring Harb Perspect Med, 2014, 5(7): a019752.
13 Lohse MB, Gulati M, Johnson AD, et al. Development and regulation of single-and multi-species Candida albicans biofilms[J]. Nat Rev Microbiol, 2018, 16(1): 19-31.
14 Mukherjee PK, Chandra J, Kuhn DA, et al. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols[J]. Infect Immun, 2003, 71(8): 4333-4340.
15 Ghannoum M, Roilides E, Katragkou A, et al. The role of echinocandins in Candida biofilm-related vas-cular catheter infections: in vitro and in vivo model systems[J]. Clin Infect Dis, 2015, 61(): S618-S621.
16 Tsui C, Kong EF, Jabra-Rizk MA. Pathogenesis of Candida albicans biofilm[J]. Pathog Dis, 2016, 74(4): ftw018.
17 Taff HT, Mitchell KF, Edward JA, et al. Mechanisms of Candida biofilm drug resistance[J]. Future Microbiol, 2013, 8(10): 1325-1337.
18 Vediyappan G, Rossignol T, D’Enfert C. Interaction of Candida albicans biofilms with antifungals: transcriptional response and binding of antifungals to beta-glucans[J]. Antimicrob Agents Chemother, 2010, 54(5): 2096-2111.
19 Nobile CJ, Johnson AD. Candida albicans biofilms and human disease[J]. Annu Rev Microbiol, 2015, 69: 71-92.
20 Nett J, Lincoln L, Marchillo K, et al. Putative role of beta-1,3 glucans in Candida albicans biofilm resistance[J]. Antimicrob Agents Chemother, 2007, 51(2): 510-520.
21 Wachtler B, Wilson D, Haedicke K, et al. From attachment to damage: defined genes of Candida albicans mediate adhesion, invasion and damage during interaction with oral epithelial cells[J]. PLoS One, 2011, 6(2): e17046.
22 Liu Y, Filler SG. Candida albicans Als3, a multifunctional adhesin and invasion[J]. Eukaryot Cell, 2011, 10(2): 168-173.
23 Lu Y, Zhou Z, Mo L, et al. Fluphenazine antagonizes with fluconazole but synergizes with amphotericin B in the treatment of candidiasis[J]. Appl Microbiol Biotechnol, 2019, 103(16): 6701-6709.
24 Coste AT, Karababa M, Ischer F, et al. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2[J]. Eukaryot Cell, 2004, 3(6): 1639-1652.
25 Del Sorbo G, Schoonbeek HJ, De Waard MA. Fungal transporters involved in efflux of natural toxic compounds and fungicides[J]. Fungal Genet Biol, 2000, 30(1): 1-15.
26 Prasad R, Rawal MK. Efflux pump proteins in antifungal resistance[J]. Front Pharmacol, 2014, 5: 202.
27 Wirsching S, Michel S, Morschhauser J. Targeted gene disruption in Candida albicans wild-type strai-ns: the role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates[J]. Mol Microbiol, 2000, 36(4): 856-865.
28 Hemenway CS, Heitman J. Calcineurin. Structure, function, and inhibition[J]. Cell Biochem Biophys, 1999, 30(1): 115-151.
29 Liu S, Hou Y, Liu W, et al. Components of the calcium-calcineurin signaling pathway in fungal cells and their potential as antifungal targets[J]. Eukaryot Cell, 2015, 14(4): 324-334.
30 Blankenship JR, Wormley FL, Boyce MK, et al. Calcineurin is essential for Candida albicans survival in serum and virulence[J]. Eukaryot Cell, 2003, 2(3): 422-430.
31 Jia W, Zhang H, Li C, et al. The calcineruin inhibitor cyclosporine a synergistically enhances the susceptibility of Candida albicans biofilms to fluconazole by multiple mechanisms[J]. BMC Microbiol, 2016, 16(1): 113.
32 Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery[J]. Exp Biol Med (Maywood), 2003, 228(2): 111-133.
33 Cowen LE, Carpenter AE, Matangkasombut O, et al. Genetic architecture of Hsp90-dependent drug resistance[J]. Eukaryot Cell, 2006, 5(12): 2184-2188.
34 Cowen LE, Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi[J]. Science, 2005, 309(5744): 2185-2189.
35 Li X, Robbins N, O’Meara TR, et al. Extensive functional redundancy in the regulation of Candida albicans drug resistance and morphogenesis by lysine deacetylases Hos2, Hda1, Rpd3 and Rpd31[J]. Mol Microbiol, 2017, 103(4): 635-656.
36 Akins RA. An update on antifungal targets and mechanisms of resistance in Candida albicans [J]. Med Mycol, 2005, 43(4): 285-318.
37 Hoot SJ, Smith AR, Brown RP, et al. An A643V amino acid substitution in Upc2p contributes to azole resistance in well-characterized clinical isolates of Candida albicans [J]. Antimicrob Agents Chemother, 2011, 55(2): 940-942.
38 Lohberger A, Coste AT, Sanglard D. Distinct roles of Candida albicans drug resistance transcription factors TAC1, MRR1, and UPC2 in virulence[J]. Eukaryot Cell, 2014, 13(1): 127-142.
39 Vasicek EM, Berkow EL, Flowers SA, et al. UPC2 is universally essential for azole antifungal resistance in Candida albicans [J]. Eukaryotic Cell, 2014, 13(7): 933-946.
40 Oliveira-Carvalho V, Del Negro GMB. Is the S405F mutation in Candida albicans ERG11 gene sufficient to confer resistance to fluconazole[J]. J Mycol Med, 2014, 24(3): 241-242.
41 Ying Y, Zhao YJ, Hu XF, et al. In vitro fluconazole susceptibility of 1 903 clinical isolates of Candida albicans and the identification of ERG11 mutations[J]. Microb Drug Resist, 2013, 19(4): 266-273.
42 Liu S, Yue L, Gu W, et al. Synergistic effect of fluconazole and calcium channel blockers against resistant candida albicans[J]. PLoS One, 2016, 11(3): e0150859.
43 Liu S, Hou Y, Chen X, et al. Combination of fluconazole with non-antifungal agents: a promising approach to cope with resistant Candida albicans infections and insight into new antifungal agent discovery[J]. Int J Antimicrob Agents, 2014, 43(5): 395-402.
44 Holmes AR, Cardno TS, Strouse JJ, et al. Targeting efflux pumps to overcome antifungal drug resistance[J]. Future Med Chem, 2016, 8(12): 1485-1501.
45 Liu RH, Shang ZC, Li TX, et al. In vitro antibiofilm activity of eucarobustol E against Candida albicans [J]. Antimicrob Agents Chemother, 2017, 61(8): e02707-e02716.
46 Xu J, Liu R, Sun F, et al. Eucalyptal D enhances the antifungal effect of fluconazole on fluconazole-resistant Candida albicans by competitively inhibiting efflux pump[J]. Front Cell Infect Microbiol, 2019, 9: 211.
47 Yang DL, Hu YL, Yin ZX, et al. Cis-2-dodecenoic acid mediates its synergistic effect with triazoles by interfering with efflux pumps in fluconazole-resistant Candida albicans [J]. Biomed Environ Sci, 2019, 32(3): 199-209.
48 Gong Y, Liu W, Huang X, et al. Antifungal activity and potential mechanism of N-butylphthalide alone and in combination with fluconazole against Candida albicans [J]. Front Microbiol, 2019, 10: 1461.
49 Li X, Yu C, Huang X, et al. Synergistic effects and mechanisms of budesonide in combination with fluconazole against resistant Candida albicans [J]. PLoS One, 2016, 11(12): e0168936.
50 Zhao R, Davey M, Hsu YC, et al. Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone[J]. Cell, 2005, 120(5): 715-727.
51 Cruz MC, Goldstein AL, Blankenship JR, et al. Calcineurin is essential for survival during membrane stress in Candida albicans [J]. EMBO J, 2002, 21(4): 546-559.
52 Siegal ML, Promislow DE, Bergman A. Functional and evolutionary inference in gene networks: does topology matter[J]. Genetica, 2007, 129(1): 83-103.
53 Ebrahimi-Shaghaghi F, Noormohammadi Z, Atyabi SM, et al. Inhibitory effects of cold atmospheric plasma on the growth, virulence factors and HSP90 gene expression in Candida albicans [J]. Arch Biochem Biophys, 2021, 700: 108772.
54 O’Meara TR, Robbins N, Cowen LE. The Hsp90 chaperone network modulates candida virulence traits[J]. Trends Microbiol, 2017, 25(10): 809-819.
55 Zierer BK, Rubbelke M, Tippel F, et al. Importance of cycle timing for the function of the molecular chaperone Hsp90[J]. Nat Struct Mol Biol, 2016, 23(11): 1020-1028.
56 Whitesell L, Robbins N, Huang DS, et al. Structural basis for species-selective targeting of Hsp90 in a pathogenic fungus[J]. Nat Commun, 2019, 10(1): 402.
57 Garnaud C, Garcia-Oliver E, Wang Y, et al. The rim pathway mediates antifungal tolerance in Candida albicans through newly identified rim101 transcriptional targets, including Hsp90 and Ipt1[J]. Antimicrob Agents Chemother, 2018, 62(3): e01785-17.
58 Becker JW, Rotonda J, McKeever BM, et al. FK-506-binding protein: three-dimensional structure of the complex with the antagonist L-685818[J]. J Biol Chem, 1993, 268(15): 11335-11339.
59 Juvvadi PR, Fox D 3rd, Bobay BG, et al. Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agents[J]. Nat Commun, 2019, 10(1): 4275.
60 Li L, Zhang T, Xu J, et al. The synergism of the small molecule ENOblock and fluconazole against fluconazole-resistant Candida albicans [J]. Front Microbiol, 2019, 10: 2071.
61 Lu MJ, Yu CX, Cui XY, et al. Gentamicin synergises with azoles against drug-resistant Candida albicans [J]. Int J Antimicrob Agents, 2018, 51(1): 107-114.
62 Zhang M, Yan H, Lu M, et al. Corrigendum to “Antifungal activity of ribavirin used alone or in combination with fluconazole against Candida albicans is mediated by reduced virulence”[J]. Int J Antimicrob Agents, 2020, 55(3): 105917.
63 Zarnowski R, Sanchez H, Covelli AS, et al. Candida albicans biofilm-induced vesicles confer drug resistance through matrix biogenesis[J]. PLoS Biol 2018, 16(10): e2006872.
64 Deveau A, Hogan DA. Linking quorum sensing regulation and biofilm formation by Candida albicans [J]. Methods Mol Biol, 2011, 692: 219-233.
65 Singh BN, Upreti DK, Singh BR, et al. Quercetin sensitizes fluconazole-resistant Candida albicans to induce apoptotic cell death by modulating quorum sensing[J]. Antimicrob Agents Chemother, 2015, 59(4): 2153-2168.
66 Sharma M, Prasad R. The quorum-sensing molecule farnesol is a modulator of drug efflux mediated by ABC multidrug transporters and synergizes with drugs in Candida albicans [J]. Antimicrob Agents Chemother, 2011, 55(10): 4834-4843.
67 Yu LH, Wei X, Ma M, et al. Possible inhibitory molecular mechanism of farnesol on the development of fluconazole resistance in Candida albicans biofilm[J]. Antimicrob Agents Chemother, 2012, 56(2): 770-775.
68 Jia C, Zhang J, Zhuge Y, et al. Synergistic effects of geldanamycin with fluconazole are associated with reactive oxygen species in Candida tropicalis resistant to azoles and amphotericin B[J]. Free Radic Res, 2019, 53(6): 618-628.
69 Lee W, Woo ER, Lee DG. Effect of apigenin isolated from aster yomena against Candida albicans: apigenin-triggered apoptotic pathway regulated by mitochondrial calcium signaling[J]. J Ethnopharmacol, 2019, 231: 19-28.
70 Denning DW, Bromley MJ. How to bolster the antifungal pipeline[J]. Science, 2015, 347(6229): 1414-1416.
71 Ahmad A, Khan A, Manzoor N, et al. Evolution of ergosterol biosynthesis inhibitors as fungicidal aga-inst Candida[J]. Microb Pathog, 2010, 48(1): 35-41.
72 Ahmad A, Khan A, Khan LA, et al. In vitro synergy of eugenol and methyleugenol with fluconazole against clinical Candida isolates [J]. J Med Microbiol, 2010, 59(10): 1178-1184.
73 Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment[J]. Am J Med, 2012, 125(1 ): S3-S13.
74 Ahmad A, Wani MY, Khan A, et al. Synergistic interactions of eugenol-tosylate and its congeners with fluconazole against Candida albicans [J]. PLoS One, 2015, 10(12): e0145053.
75 Nishimoto AT, Wiederhold NP, Flowers SA, et al. In vitro activities of the novel investigational tetrazoles VT-1161 and VT-1598 compared to the triazole antifungals against azole-resistant strains and clinical iolates of Candida albicans [J]. Antimicrob Agents Chemother, 2019, 63(6): e00341-19.
76 Prasad R, Shah AH, Rawal MK. Antifungals: mechanism of action and drug resistance[J]. Adv Exp Med Biol, 2016, 892: 327-349.
77 Silva S, Henriques M, Hayes A, et al. Candida glabrata and Candida albicans co-infection of an in vitro oral epithelium[J]. J Oral Pathol Med, 2011, 40(5): 421-427.
78 Pathak AK, Sharma S, Shrivastva P. Multi-species biofilm of Candida albicans and non-Candida albicans Candida species on acrylic substrate[J]. J Appl Oral Sci, 2012, 20(1): 70-75.
79 Cieslik W, Szczepaniak J, Krasowska A, et al. Antifungal styryloquinolines as Candida albicans efflux pump inhibitors: styryloquinolines are ABC transporter inhibitors[J]. Molecules, 2020, 25(2): 345.
80 Day AM, Quinn J. Stress-activated protein kinases in human fungal pathogens[J]. Front Cell Infect Microbiol, 2019, 9: 261.
81 Navarro-Garcia F, Sanchez M, Pla J, et al. Functional characterization of the MKC1 gene of Candida albicans, which encodes a mitogen-activated protein kinase homolog related to cell integrity[J]. Mol Cell Biol, 1995, 15(4): 2197-2206.
82 Correia I, Wilson D, Hube B, et al. Characterization of a Candida albicans mutant defective in all MA-PKs highlights the major role of Hog1 in the MAPK signaling network[J]. J Fungi (Basel), 2020, 6(4): 230.
83 Gopal D, Muddebihalkar AG, Skariyachan S, et al. Mitogen activated protein kinase-1 and cell division control protein-42 are putative targets for the binding of novel natural lead molecules: a therapeutic intervention against Candida albicans [J]. J Biomol Struct Dyn, 2020, 38(15): 4584-4599.
84 Correia I, Prieto D, Roman E, et al. Cooperative role of MAPK pathways in the interaction of Candida albicans with the host epithelium[J]. Microorganisms, 2019, 8(1): 48.
85 Roman E, Correia I, Prieto D, et al. The HOG MAPK pathway in Candida albicans: more than an osmosensing pathway[J]. Int Microbiol, 2020, 23(1): 23-29.
86 Dai BD, Wang Y, Li DD, et al. Hsp90 is involved in apoptosis of Candida albicans by regulating the calcineurin-caspase apoptotic pathway[J]. PLoS One, 2012, 7(9): e45109.
87 Jordao CC, Klein MI, Carmello JC, et al. Consecutive treatments with photodynamic therapy and nystatin altered the expression of virulence and ergosterol biosynthesis genes of a fluconazole-resistant Candida albicans in vivo [J]. Photodiagn Photodyn, 2021, 33: a102155.
[1] Li Shanshan,Yang Fang. Research progress on the relationship between Streptococcus mutans and Candida albicans in caries [J]. Int J Stomatol, 2022, 49(4): 392-396.
[2] Liu Qianxi,Wu Jiayi,Ren Biao,Huang Ruijie. Research progress on the interactions between Enterococcus faecalis and other oral microorganisms [J]. Int J Stomatol, 2022, 49(3): 290-295.
[3] Huang Peiqing,Peng Xian,Xu Xin. Volatile sulfur compounds and its role in the management of intra-oral halitosis [J]. Int J Stomatol, 2021, 48(5): 592-599.
[4] Li Shijia,Chen Qiuyu,Zou Jing,Huang Ruijie. Effect of nicotine on the growth of oral bacteria in single or mixed species [J]. Int J Stomatol, 2021, 48(3): 305-311.
[5] Xiong Kaixin,Zou Ling. Correlation between Candida albicans, Actinomyces viscosus, and root caries [J]. Int J Stomatol, 2021, 48(2): 187-191.
[6] Li Fan,Zhang Lijuan,Tan Kaixuan,Zhang Ying,Lu Jie,Li Shanshan,Yang Fang. Antimicrobial effect of chlorhexidine on Candida albicans in vitro according to D2O-labeled single-cell Raman micro-spectroscopy [J]. Int J Stomatol, 2021, 48(1): 35-40.
[7] Hu Yao,Cheng Lei,Guo Qiang,Ren Biao. Research progress on cross-kingdom interactions between Candida albicans and common oral bacteria [J]. Int J Stomatol, 2019, 46(6): 663-669.
[8] Wen Shuqiong,Guo Junyi,Dai Wenxiao,Wang Dikan,Wang Zhi. Research progress on the mechanism of Candida albicans in oral carcinogenesis [J]. Int J Stomatol, 2019, 46(6): 705-710.
[9] Qian Du,Biao Ren,Xuedong Zhou,Xin Xu. The microbial ecology of root caries [J]. Int J Stomatol, 2019, 46(3): 326-332.
[10] Yilong Hao,Yu Zhou,Qianming Chen. Research progress on the risk factors of median rhomboid glossitis [J]. Int J Stomatol, 2019, 46(3): 333-338.
[11] Zi Yang,Benxiang Hou. Research progress on the extra- and intra-radicular biofilm associated with persistent apical periodontitis [J]. Inter J Stomatol, 2019, 46(2): 238-243.
[12] Jing Wang,Yan Wang,Chuandong Wang,Ruijie Huang,Yan Tian,Wei Hu,Jing Zou. Application of liquorice and its extract to the prevention and treatment of oral infections and associated diseases [J]. Inter J Stomatol, 2018, 45(5): 546-552.
[13] Fang Hongzhi, Tian Yuanyuan, Yu Xuan, Yang Yingming, Yang Hui, Hu Tao. The influence of exogenous dextranase and sodium fluoride on biofilm of Actinomyces viscosus under different sucrose concentration conditions [J]. Inter J Stomatol, 2017, 44(6): 654-659.
[14] Liu Shiyu, Tian Mi, Shi Liran, Pan Weilin, Wang Yiyao, Li Mingyun. Effect of nicotine and mecamylamine on growth of periodontal pathogens [J]. Inter J Stomatol, 2017, 44(4): 421-425.
[15] Lu Xiao, Weng Chunhui, Wang Jinming, Liu Shaojuan, Liu Qin, Lin Shan. Biofilm formation and antimicrobial susceptibility of Streptococcus mitis in response to luxS/AI-2 signaling [J]. Inter J Stomatol, 2017, 44(4): 411-420.
Full text



[1] . [J]. Foreign Med Sci: Stomatol, 2006, 33(04): 272 -274 .
[2] Ao Tongjiang, Yuan Xiaoping, Yang Siwei, Huang Yue.. Effects of orthodontic treatment on the condylar and mandibular positions of patients with class Ⅲ malocclusion in mixed dentition[J]. Inter J Stomatol, 2012, 39(4): 439 -442 .
[3] Liu Zhenzhang1, Yuan Xiaoping2. . A method for the construction of a 3D finite element model with higher efficiency[J]. Inter J Stomatol, 2012, 39(2): 177 -179 .
[4] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[5] Liu Lin1, Wang Shengyu2, Yuan Xiaoping1.. Effects of parathyroid hormone and parathyroid hormone related protein in the related cells of tooth repair[J]. Inter J Stomatol, 2012, 39(3): 376 -379 .
[6] CHEN Yi-jia, ZHU Shuang-lin. Usage of ultrasound in estimating the function of temporomandibular joint[J]. Inter J Stomatol, 2008, 35(6): 660 -660~661,664 .
[7] . [J]. Inter J Stomatol, 2008, 35(S1): .
[8] Cheng Yuan, Yin Yanli, Zhao Lei. Research progress on Filifactor alocis[J]. Inter J Stomatol, 2014, 41(5): 593 -597 .
[9] Lü Jingjing, Mi Congbo. Research progress on biomechanics of periodontal ligament[J]. Inter J Stomatol, 2014, 41(3): 362 -364 .
[10] Zhang Lihua1, Xu Xiaomei2, Song Siquan3, Yang Siwei2.. Influence of psychological interventions on orthodontic treatment pain experienced by patients of different sexes[J]. Inter J Stomatol, 2014, 41(4): 396 -400 .